Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD

NCT05874999 | Completed

• 1 other identifier: COPD-HIIT ACUTE
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system. The aims of this cross-over trial is:

1. 1.To compare the acute effects of short-duration supramaximal high-intensity interval training (HIIT) vs. traditional moderate-intensity continuous training (MICT) in people with COPD and matched healthy controls (HC).
2. 2.To investigate the feasibility of supramaximal HIIT in people with COPD and matched HC.
3. 3.To compare the cardiorespiratory demand, exercise intensity and symptoms during a modified Borg Cycle Strength Test (BCST) and a cardiopulmonary exercise test (CPET) in people with COPD and HC.

Conditions

COPD; Healthy Older Adults

Keywords

Acute Exercise; High-intensity Interval Training

Outcome Measures

Primary Outcomes (6)

• Exercise intensity

  Produced watt at the set training intensity

  During visit 2 (week 1)

• Exercise intensity

  Produced watt at the set training intensity

  During visit 3 (week 2)

• Exercise intensity

  Produced watt at the set training intensity

  During visit 4 (week 2)

• Brain-derived neurotrophic factor (BDNF)

  Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL.

  During visit 2 (week 1)

• Brain-derived neurotrophic factor (BDNF)

  Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL.

  During visit 3 (week 2)

• Brain-derived neurotrophic factor (BDNF)

  Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL.

  During visit 4 (week 2)

Secondary Outcomes (14)

• Cardiorespiratory demand

  During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)

• Venous blood lactate concentration

  During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)

• Rating of perceived exertion

  During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)

• Rating of symptoms

  During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)

• Peripheral blood oxygen saturation (SpO2)

  During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)

Study Arms (2)

Chronic Obstructive Pulmonary Disease (COPD)

EXPERIMENTAL

People with chronic obstructive pulmonary disease (COPD) (n = 16)

Other: Supramaximal High-Intensity Interval Training at 60% of MPO6; Other: Moderate-Intensity Continuous Training; Other: Supramaximal High-Intensity Interval Training at 80% of MPO6

Healthy Controls (HC)

ACTIVE COMPARATOR

Healthy controls matched on age, sex and objectively measured physical activity (n = 16)

Other: Supramaximal High-Intensity Interval Training at 60% of MPO6; Other: Moderate-Intensity Continuous Training; Other: Supramaximal High-Intensity Interval Training at 80% of MPO6

Interventions

Supramaximal High-Intensity Interval Training at 60% of MPO6 OTHER

Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle.

Also known as: Supramaximal High-Intensity Interval Training at 60% of MPO6 (HIIT60%)

Chronic Obstructive Pulmonary Disease (COPD); Healthy Controls (HC)

Moderate-Intensity Continuous Training OTHER

MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle. Duration MICT: 20 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle.

Also known as: MICT

Chronic Obstructive Pulmonary Disease (COPD); Healthy Controls (HC)

Supramaximal High-Intensity Interval Training at 80% of MPO6 OTHER

Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle.

Also known as: Supramaximal High-Intensity Interval Training at 80% of MPO6 (HIIT80%)

Chronic Obstructive Pulmonary Disease (COPD); Healthy Controls (HC)

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• COPD with non-reversible airflow obstruction diagnosis (post-bronchodilator forced expiratory volume during the first second/forced vital capacity (FEV1/FVC) \< 0.7)
• Age: \> 40 years

You may not qualify if:

• Recent exacerbation of COPD (\< 6 weeks)
• Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
• Recent lung cancer (\< 5 years)
• Unstable cardiac disease and/or cardiac stimulator
• \- Age: \> 40 years
• Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
• Any respiratory disease
• Recent lung cancer (\< 5 years)
• Unstable cardiac disease and/or cardiac stimulator
• Too low or high physical activity level that prohibits matching

Sponsors & Collaborators

• Umeå University: lead
• The Swedish Research Council: collaborator
• Swedish Heart Lung Foundation: collaborator
• Riksförbundet HjärtLung: collaborator

Study Sites (1)

Umeå University

Umeå, Sweden

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Andre Nyberg, PhD

  Umeå University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: March 30, 2023
• First Posted: May 25, 2023
• Study Start: March 7, 2022
• Primary Completion: December 22, 2022
• Study Completion: December 22, 2022
• Last Updated: June 7, 2023

Record last verified: 2023-06

Locations

SE (1)